Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15275698 | 0.84 | NPC1 (0.43) | MAOBKMT2ARAB9AALDH1A1NPC1 | |
| SCHEMBL15275699 | 0.84 | CA1 (0.41) | MAOBRAB9AALDH1A1NPC1GAA | |
| SCHEMBL8578279 | 0.81 | MAOB (0.51) | MAOBMEN1MAPK10KMT2AALDH1A1 | |
| SCHEMBL27901151 | 0.72 | NOS3 (0.39) | MAOBNISCHRAB9AALDH1A1NPC1 | |
| SCHEMBL30594257 | 0.69 | MAOB (0.39) | MAOBMEN1KMT2ANISCHRAB9A | |
| SCHEMBL24363868 | 0.69 | NISCH (0.43) | MAOBMEN1KMT2ANISCHRAB9A | |
| SCHEMBL8578277 | 0.69 | MAOB (0.50) | MAOBMEN1MAPK10KMT2AALDH1A1 | |
| SCHEMBL14214318 | 0.69 | MAOB (0.50) | MAOBMEN1MAPK10KMT2AALDH1A1 | |
| SCHEMBL25323171 | 0.69 | NISCH (0.43) | MAOBMEN1KMT2ANISCHRAB9A | |
| SCHEMBL8243017 | 0.68 | MIF (0.52) | MAOBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212348-B2 | Method for producing hematopoietic stem cells using pyrazole compounds | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212348-B2 | Method for producing hematopoietic stem cells using pyrazole compounds | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20140057353-A1 | METHOD FOR PRODUCING HEMATOPOIETIC STEM CELLS USING PYRAZOLE COMPOUNDS | REPROCELL INCORPORATED (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140057353-A1 | METHOD FOR PRODUCING HEMATOPOIETIC STEM CELLS USING PYRAZOLE COMPOUNDS | REPROCELL INCORPORATED (JP) | 2014-02-27 | — | — | US | disclosed |
| US-8658686-B2 | Pyrazole compounds having therapeutic effect on multiple myeloma | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-02-25 | — | — | US | disclosed |
| US-8658686-B2 | Pyrazole compounds having therapeutic effect on multiple myeloma | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-02-25 | — | — | US | disclosed |
| US-20130253204-A1 | PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-26 | — | — | US | disclosed |
| US-20130253204-A1 | PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-26 | — | — | US | disclosed |
| WO-2012074067-A1 | PYRAZOLE COMPOUND HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA | 日産化学工業株式会社 (JP) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012074068-A1 | METHOD FOR PRODUCING HEMATOPOIETIC STEM CELLS USING PYRAZOLE COMPOUND | 日産化学工業株式会社 (JP) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253204-A1 | PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA | MCL1, BCL6, RTN3 | MAOB 4791/4885MEN1 377/4885MAPK10 1708/4885 |
| US-20140057353-A1 | METHOD FOR PRODUCING HEMATOPOIETIC STEM CELLS USING PYRAZOLE COMPOUNDS | HCLS1, RUNX1, HPRT1 | MAOB 4031/4885MEN1 2920/4885MAPK10 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.